Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome

NCT02666950 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.

NCT NCT02666950
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02666950 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of WEE1 Inhibition With AZD1775 Alone or Combined With Cytarabine in Patients With Advanced Acute Myeloid Leukemia and Myelodysplastic Syndrome
Lead sponsor
Mayo Clinic
Phase
Phase 2
Overall status
Completed
Start date
May 5, 2017
Completion date
October 17, 2018
Enrollment
3 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic myelomonocytic leukemia, myelodysplastic syndrome with isolated del(5q), myelodysplastic/myeloproliferative neoplasm, previously treated myelodysplastic syndrome, recurrent adult acute myeloid leukemia, untreated adult acute myeloid leukemia